nach oben

Erschienen in:

01.10.2007 | Original Article

Intra-articular injection of hyaluronate and indomethacin in rabbits with antigen-induced arthritis

verfasst von: Yow-Jen Lo, Ming-Thau Sheu, Wen-Chi Tsai, Yun-Ho Lin, Jau-Le Li, Yu-Chih Liang, Chi-Ching Chang, Ming-Shium Hsieh, Chien-Ho Chen

Erschienen in: Rheumatology International | Ausgabe 12/2007

Einloggen, um Zugang zu erhalten

Abstract

Combined effects of hyaluronate and indomethacin in the treatment of rabbits with antigen-induced arthritis (AIA) were evaluated by assessing joint swelling, C-reactive protein (CRP) and prostaglandin E₂ (PGE₂) levels with periodic intra-articular (ia) injections of hyaluronate alone (HA group) and with either a low or high concentration of indomethacin (LI-HA or HI-HA group). End-point analyses included matrix metalloproteinases-3 (MMP-3) activity and macroscopic and histological joint examinations. Results demonstrated that treatment in LI-HA and HI-HA groups resulted in statistically significant suppression of CRP, PGE_2,and MMP-3 in comparison with those of HA group. Inhibition of serum CRP was only observed in LI-HA group. The order of serum MMP-3 inhibition was LI-HA>HI-HA>HA. Based on macroscopic and histological analyses of pannus formation, hyperplasia, inflammation, joint leakage and erosion, and loss of proteoglycan, the only statistically significant improvement was shown in LI-HA group compared to HA group and HI-HA group compared to control group.

Walker JM, Helewa A (1996) Physical therapy in arthritis. Saunders, Philadelphia

Shahbaz H, James WS (2001) Septic arthritis. Curr Treat Opt Infect Dis 3:279–286

Goldring SR, Gravallese EM (2000) Mechanisms of bone loss in inflammatory arthritis: diagnosis and therapeutic implications. Arthritis Res 2:33–37PubMedCrossRef

Brandt KD, Smith GN Jr, Simon LS (2000) Intraarticular injection of hyaluronan as treatment for knee osteoarthritis: what is the evidence? Arthritis Rheum 43:1192–1203PubMedCrossRef

Ceponis A, Waris E, Monkkonen J, Laasonen L, Hyttinen M, Solovieva SA, Hanemaaijer R, Bitsch A, Konttinen YT (2001) Effects of low-dose, noncytotoxic, intraarticular liposomal clodronate on development of erosions and proteoglycan loss in established antigen-induced arthritis in rabbits. Arthritis & Rheum 44:1908–1916CrossRef

Campo GM, Avenoso A, Campo S, Ferlazzo AM, Altavilla D, Calatroni A (2003) Efficacy of treatment with glycosaminoglycans on experimental collagen-induced arthritis in rats. Arthritis Res Ther 5:R122–R131PubMedCrossRef

Moreland LW (2003) Intra-articular hyaluronan (hyaluronic acid) and hylans for the treatment of osteoarthritis: mechanisms of action. Arthritis Res Ther 5:54–67PubMedCrossRef

Aggarwal A, Sempowski IP (2004) Hyaluronic acid injections for knee osteoarthritis. Systematic review of the literature Can Fam Physician 50:249–256PubMed

Yasui T, Akatsuka M, Tobetto K, Hayaishi M, Ando T (1992) The effect of hyaluronan on interleukin-1 alpha-induced prostaglandin E2 production in human osteoarthritic synovial cells. Agents Actions 37:155–156PubMedCrossRef

10.

Tobetto K, Yasui T, Ando T, Hayaishi M, Motohashi N, Shinogi M, Mori I (1992) Inhibitory effects of hyaluronan on [14C] arachidonic acid release from labeled human synovial fibroblasts. Jpn J Pharmacol 60:79–84PubMed

11.

Larsen NE, Lombard KM, Parent EG, Balazs EA (1992) Effect of hylan on cartilage and chondrocyte cultures. J Orthop Res 10:23–32PubMedCrossRef

12.

Presti D, Scott JE (1994) Hyaluronan-mediated protective effect against cell damage caused by enzymatically produced hydroxyl (OH^.) radicals is dependent on hyaluronan molecular mass. Cell Biochem Funct 12:281–288PubMedCrossRef

13.

Gomis A, Pawlak M, Balazs EA, Schmidt RF, Belmonte C (2004) Effects of different molecular weight elastoviscous hyaluronan solutions on articular nociceptive afferents. Arthritis Rheum 50:314–326PubMedCrossRef

14.

Roth A, Mollenhauer J, Wagner A, Fuhrmann R, Straub A, Venbrocks RA, Petrow P, Bräuer R, Schubert H, Ozegowski J, Peschel G, Müller PJ, Kinne RW (2005) Intra-articular injections of high-molecular-weight hyaluronic acid have biphasic effects on joint inflammation and destruction in rat antigen-induced arthritis. Arthritis Res Ther 7:R677–R686PubMedCrossRef

15.

Williams HJ, Ward JR, Egger MJ, Neuner R, Brooks RH, Clegg DO, Field EH, Skosey JL, Alarcon GS, Paulus HE, Russell IJ, Sharp JT (1993) Comparison of naproxen and acetaminophen in a two-year study of treatment of osteoarthritis of the knee. Arthritis & Rheum 36:1196–1206CrossRef

16.

Zhang W, Jones A, Doherty M (2004) Does paracetamol (acetaminophen) reduce the pain of osteoarthritis? A meta-analysis of randomised controlled trials. Ann Rheum Dis 63:901–907PubMedCrossRef

17.

Wolfe F, Zhao S, Lane N (2000) Preference for nonsteroidal antiinflammatory drugs over acetaminophen by rheumatic disease patients: a survey of 1,799 patients with osteoarthritis, rheumatoid arthritis, and fibromyalgia. Arthritis Rheum 43:378–385PubMedCrossRef

18.

Huang SH (2000) Rheumatology: 7. Basics of therapy. CMAJ 163:417–423PubMed

19.

Yoon JB, Kim SJ, Hwang SG, Chang S, Kang SS, Chun JS (2003) Non-steroidal anti-inflammatory drugs inhibit nitric oxide-induced apoptosis and dedifferentiation of articular chondrocytes independent of cyclooxygenase activity. J Biol Chem 278:15319–15325PubMedCrossRef

20.

Dawson J, Engelhardt P, Kastelic T, Cheneval D, MacKenzie A, Ramage P (1999) Effects of soluble interleukin-1 type II receptor on rabbit antigen-induced arthritis: clinical, biochemical and histological assessment. Rheumatology (Oxford) 38:401–406CrossRef

21.

Shafer-Weaver KA, Sayers T, Kuhnd DB, Strobl SL, Burkett MW, Baseler M, Malyguine A (2004) Evaluating the cytotoxicity of innate immune effector cells using the GrB ELISPOT assay. J Transl Med 2:31PubMedCrossRef

22.

Hanke JH, Gardner JP, Dow RL, Changelian PS, Brissette WH, Weringer EJ, Pollok BA, Connelly PA (1996) Discovery of a novel, potent, and Src family-selective tyrosine kinase inhibitor. Study of Lck- and FynT-dependent T cell activation. J Biol Chem 271:695–701PubMedCrossRef

23.

Ribbens C, Porras M, Martin Y, Franchimont N, Kaiser MJ, Jaspar JM, Damas P, Houssiau FA, Malaise MG (2002) Increased matrix metalloproteinase-3 serum levels in rheumatic diseases: relationship with synovitis and steroid treatment. Ann Rheum Dis 61:161–166PubMedCrossRef

24.

Posthumus MD, Limburg PC, Westra J, Cats HA, Stewart RE, van Leeuwen MA, van Rijswijk MH (1999) Serum levels of matrix metalloproteinase-3 in relation to the development of radiological damage in patients with early rheumatoid arthritis. Rheumatology 38(11):1081–1087PubMedCrossRef

25.

Atkinson JP (2001) C-Reactive protein: a Rheumatologist’s friend revisited. Arthritis Rheum 44:995–996PubMedCrossRef

26.

Weinhold B, Bader A, Poli V, Ruther U (1997) Interleukin-6 is necessary, but not sufficient, for induction of the human C-reactive protein gene in vivo. Biochem J 325:617–621PubMed

27.

de Silva KI, Daud AN, Deng JP, Jones SB, Gamelli RL, Shankar R (2003) Prostaglandin E₂ mediates growth arrest in NFS-60 cells by down-regulating interleukin-6 receptor expression. Biochem J 370:315–321PubMedCrossRef

28.

Familian A, Voskuyl AE, van Mierlo GJ, Heijst HA, Twisk JW, Dijkmans BA, Hack CE (2005) Infliximab treatment reduces complement activation in patients with rheumatoid arthritis. Ann Rheum Dis 64:1003–1008PubMedCrossRef

29.

Yamanaka H, Matsuda Y, Tanaka M, Sendo W, Nakajima H, Taniguchi A, Kamatani N (2000) Serum matrix metalloproteinase 3 as a predictor of the degree of joint destruction during the six months after measurement, in patients with early rheumatoid arthritis. Arthritis Rheum 43:852–858PubMedCrossRef

30.

31.

Catrina AI, Lampa J, Ernestam S, af Klint E, Bratt J, Klareskog L, Ulfgren AK (2002) Anti-tumour necrosis factor (TNF)-alpha therapy (etanercept) down-regulates serum matrix metalloproteinase (MMP)-3 and MMP-1 in rheumatoid arthritis. Rheumatology (Oxford) 41:484–489CrossRef

32.

Vincenti MP, Clark IM, Brinckerhoff CE (1994) Using inhibitors of metalloproteinases to treat arthritis. Easier said than done? Arthritis Rheum 37:1115–1126PubMedCrossRef

33.

Cawston T (1998) Matrix metalloproteinases and TIMPs: properties and implications for the rheumatic diseases. Mol Med Today 4:130–137PubMedCrossRef

34.

Sasaki S, Iwata H, Ishiguro N, Obata K, Miura T (1994) Detection of stromelysin in synovial fluid and serum from patients with rheumatoid arthritis and osteoarthritis. Clin Rheumatol 13:228–233PubMed

35.

Ribbens C, Andre B, Jaspar JM, Kaye O, Kaiser MJ, De Groote D, Malaise MG (2000) Matrix metalloproteinase-3 serum levels are correlated with disease activity and predict clinical response in rheumatoid arthritis. J Rheumatology 27:888–893

36.

Taylor DJ, Cheung NT, Dawes PT (1994) Increased serum proMMP-3 in inflammatory arthritis: a potential indicator of synovial inflammatory monokine activity. Ann Rheum Dis 53:768–772PubMedCrossRef

37.

Han F, Ishiguro N, Ito T, Sakai T, Iwata H (1999) Effects of sodium hyaluronate on experimental osteoarthritis in rabbit knee joints. Nagoya J Med Sci 62:115–126PubMed

38.

Takahashi K, Goomer RS, Harwood F, Kubo T, Hirasawa Y, Amiel D (1999) The effects of hyaluronan on matrix metalloproteinase-3 (MMP-3), interleukin-1beta(IL-1beta), and tissue inhibitor of metalloproteinase-1 (TIMP-1) gene expression during the development of osteoarthritis. Osteoarthritis Cartilage 7:182–190PubMedCrossRef

39.

Qiu B, Liu SQ, Peng H, Wang HB (2005) The effects of sodium hyaluronate on mRNA expressions of matrix metalloproteinase-1, -3 and tissue inhibitor of metalloproteinase-1 in cartilage and synovium of traumatic osteoarthritis model. Chin J Traumatol 8:8–12PubMed

40.

Sasaki A, Sasaki K, Konttinen YT, Santavirta S, Takahara M, Takei H, Ogino T, Takagi M (2004) Hyaluronate inhibits the interleukin-1beta-induced expression of matrix metalloproteinase (MMP)-1 and MMP-3 in human synovial cells. Tohoku J Exp Med 204:99–107PubMedCrossRef

41.

Monfort J, Nacher M, Montell E, Vila J, Verges J, Benito P (2005) Chondroitin sulfate and hyaluronic acid (500–730 kDa) inhibit stromelysin-1 synthesis in human osteoarthritic chondrocytes. Drugs Exp Clin Res 31:71–76PubMed

42.

Sadowski T, Steinmeyer J (2001) Effects of non-steroidal antiinflammatory drugs and dexamethasone on the activity and expression of matrix metalloproteinase-1, matrix metalloproteinase-3 and tissue inhibitor of metalloproteinases-1 by bovine articular chondrocytes. Osteoarthritis & Cartilage 9:407–415CrossRef

43.

Yamada H, Kikuchi T, Nemoto O, Obata K, Sato H, Seiki M, Shinmei M (1996) Effects of indomethacin on the production of matrix metalloproteinase-3 and tissue inhibitor of metalloproteinases-1 by human articular chondrocytes. J Rheumatol 23:1739–1743PubMed

44.

Bevilacqua M, Devogelaer JP, Righini V, Famaey JP, Manicourt DH (2004) Effect of nimesulide on the serum levels of hyaluronan and stromelysin-1 in patients with osteoarthritis: a pilot study. Int J Clin Pract Suppl 144:13–19PubMedCrossRef

45.

Yan M, Noguchi K, Ruwanpura SM, Ishikawa I (2005) Cyclooxygenase-2-dependent prostaglandin (PG) E2 downregulates matrix metalloproteinase-3 production via EP2/EP4 subtypes of PGE2 receptors in human periodontal ligament cells stimulated with interleukin-1alpha. J Periodontology 76:929–935CrossRef

46.

Calabrese LH, Michel BA, Bloch DA, Arend WP, Edworthy SM, Fauci AS, Fries JF, Hunder GG, Leavitt RY, Lie JT, Lightfoot RW, Masi AT, McShave DJ, Mills JA, Stevens MB, Wallace SL, Zvaifler NJ (1990) The American College of Rheumatology 1990 criteria for the classification of hypersensitivity vasculitis. Arthritis & Rheum 33:1108–1113CrossRef

47.

Brennan FM, Browne KA, Green PA, Jaspar JM, Maini RN, Feldmann M (1997) Reduction of serum matrix metalloproteinase 3 in rheumatoid arthritis patients following anti-tumor necrosis factor-α (cA2) therapy. Br J Rheumatol 36:643–650PubMedCrossRef

48.

Partsch G, Wagner E, Leeb BF, Dunky A, Steiner G, Smolen JS (1998) Upregulation of cytokine receptors sTNF-R55, sTNF-R75, and sIL-2R in psoriatic arthritis synovial fluid. J Rheumatol 25:105–110PubMed

Titel: Intra-articular injection of hyaluronate and indomethacin in rabbits with antigen-induced arthritis
verfasst von: Yow-Jen Lo
Ming-Thau Sheu
Wen-Chi Tsai
Yun-Ho Lin
Jau-Le Li
Yu-Chih Liang
Chi-Ching Chang
Ming-Shium Hsieh
Chien-Ho Chen
Publikationsdatum: 01.10.2007
Verlag: Springer-Verlag
Erschienen in: Rheumatology International / Ausgabe 12/2007
Print ISSN: 0172-8172
Elektronische ISSN: 1437-160X
DOI: https://doi.org/10.1007/s00296-007-0346-1

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

19.04.2024 | Vorhofflimmern | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Intra-articular injection of hyaluronate and indomethacin in rabbits with antigen-induced arthritis

Abstract

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Parodontalbehandlung verbessert Prognose bei Katheterablation

Prostatakarzinom: EU initiiert neues Screeningkonzept

Blasenkarzinom – Biomarker statt Zytologie?

Antihypertensiva schützen auch alte Menschen noch vor Demenz

Update Innere Medizin

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 12/2007

Antiovarian antibodies in primary Sjogren’s syndrome

Chitotriosidase as a marker of disease activity in sarcoidosis

Ankylosing spondylitis in a patient with Turner syndrome: a case report

Diagnostic performances of anti-cyclic citrullinated peptide antibodies in rheumatoid arthritis

Epidemiological multicenter study on osteoporosis: the EDMUSTO study

Refractory retinal vasculitis due to sarcoidosis successfully treated with infliximab

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Parodontalbehandlung verbessert Prognose bei Katheterablation

Prostatakarzinom: EU initiiert neues Screeningkonzept

Blasenkarzinom – Biomarker statt Zytologie?

Antihypertensiva schützen auch alte Menschen noch vor Demenz

Update Innere Medizin